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5 %, partial response (PR) in 10 %, stable disease (SD) in 
22 %, and 63 % had progressive disease (PD). The median 
overall survival (mOS) for these patients was 19.6 months, 
with a median follow-up of 43.1 months. The mOS was 
not reached for patients achieving CR or PR, and was 
33.4 months for patients with SD. For patients with mRCC, 
6 % achieved CR, 9 % had PR, 22 % had SD, and 62 % 
had PD. The mOS was 41 months, with a median follow-
up of 46.6 months. The mOS for patients who had CR and 
PR was not reached and was 49.6 months for patients with 
SD. There were no treatment-related deaths among 362 
patients. The duration of mOS for patients with mM and 
mRCC is longer than historically reported. These data sup-
port a continued role for IL-2 in the treatment of eligible 
patients with mM or mRCC and warrant further evaluation 
of HD IL-2 in combination or sequence with other thera-
peutic agents.
Abstract High-dose interleukin-2 (HD IL-2) was approved 
for treatment of metastatic renal cell carcinoma (mRCC) in 
1992 and for metastatic melanoma (mM) in 1998, in an era 
predating targeted therapies and immune checkpoint inhibi-
tors. The PROCLAIMSM registry was established to collect 
and analyze data for patients treated with HD IL-2 in the 
current era. This analysis includes 170 patients with mM 
and 192 patients with mRCC treated between 2005 and 
2012 with survival data current as of July 27, 2015. For 
patients with mM, complete response (CR) was observed in 
The data have been presented in part at the 50th Annual Meeting 
of the American Society of Clinical Oncology, May 30–June 3, 
2014, Chicago, Illinois, USA, and appear in complete form for 
the first time in this paper.
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Abbreviations
CBR  Clinical benefit rate
CI  Confidence interval
CR  Complete response
CTLA-4  Cytotoxic T lymphocyte antigen 4
ECOG PS  Eastern Cooperative Oncology Group perfor-
mance status
HD IL-2  High-dose interleukin-2
LLN  Lower limit of normal
MAPK  Mitogen-activated protein kinase
mM  Metastatic melanoma
mOS  Median overall survival
mRCC  Metastatic renal cell carcinoma
mTOR  Mechanistic target of rapamycin
ORR  Objective response rate
PD  Progressive disease
PD-1  Programmed cell death receptor-1
PR  Partial response
RECIST  Response evaluation criteria in solid tumors
SD  Stable disease
TT  Targeted therapy
ULN  Upper limit of normal
VEGF  Vascular endothelial growth factor
WHO  World Health Organization
Introduction
Historically, treatment options for patients with metastatic 
melanoma (mM) and metastatic renal cell carcinoma (mRCC) 
were limited and the prognosis was poor with 5-year overall 
survival (OS) of 5–10 %, respectively [1]. The finding that 
some patients with these malignancies responded to high-
dose interleukin-2 (HD IL-2) ultimately led to Food and Drug 
Administration (FDA) approval of HD IL-2 for mRCC in 
1992 and then for mM in 1998. The historical response rates 
and overall survival reported at the time of approval were 
16 % and 11.4 months for mM and 15 % and 16.3 months 
for mRCC, respectively [2–4]. The trials that led to FDA 
approval were single arm, uncontrolled studies and early on 
were associated with significant therapy-related deaths, 2 and 
4 %, respectively, in melanoma and renal cell carcinoma. They 
were not analyzed for the survival impact of stable disease.
Recent studies have reported improved survival for 
patients with both malignancies treated with HD IL-2, with 
reduced treatment-related mortality and a survival ben-
efit associated with stable disease. A retrospective analysis 
performed at Providence Portland Cancer Center, which 
included 314 mM and 186 mRCC patients treated between 
1997 and 2012, reported an objective response rate (ORR) 
of 28 % for mM and 24 % for mRCC patients [5]. In a 
study of 88 mRCC patients treated at Roswell Park between 
2004 and 2011, the observed mOS was 35.5 months com-
pared to historical reference range of 16–20 months [6]. In 
a prospective multicenter study conducted by the Cytokine 
Working Group, researchers reported an ORR of 25 % 
and mOS of 42.8 months in 120 mRCC patients treated 
between 2006 and 2009 [7]. Thus, the contemporary expe-
rience with HD IL-2 suggests improved overall response 
rate and survival in mM and mRCC compared to the his-
torical data.
Following the initial observation of durable long-term 
benefit from HD IL-2, novel immunotherapies and tar-
geted therapies (TT) have been developed for the treatment 
of both mM and mRCC. Immune checkpoint inhibitors 
directed against cytotoxic T lymphocyte antigen 4 (CTLA-
4) such as ipilimumab [2011] [8, 9] or programmed cell 
death receptor-1 (PD-1) such as nivolumab [2014 for 
melanoma, 2015 for mRCC] and pembrolizumab [2014] 
[10–13] have demonstrated objective responses and dura-
ble remissions in mM and mRCC. In parallel with these 
advances in immunotherapy, the ability to target drivers 
of the mitogen-activated protein kinase (MAPK) pathway 
(vemurafenib [2011], dabrafenib [2013], trametinib [2013], 
cobimetinib [2015]) led to potential treatments for a geneti-
cally defined subset of the mM population [14–17]. For 
mRCC, inhibitors of the vascular endothelial growth fac-
tor (VEGF) pathway (axitinib [2012], sorafenib [2005], 
sunitinib [2006], bevacizumab [2009], pazopanib [2009] 
and cabozantinib [2016]) and inhibitors of the mamma-
lian target of rapamycin (mTOR) pathway (temsirolimus 
[2007] and everolimus [2009]) have been approved [18–
21]. Checkpoint inhibitors are effective as monotherapy in 
approximately 25 % of advanced melanoma patients, as yet 
undefined, and carry the risk of potentially serious toxici-
ties [22, 23]. Molecular-targeted therapies such as vemu-
rafenib show initial high response rates but patients quickly 
progress due to acquired drug resistance [24–26]. Although 
treatment options for mM and mRCC have increased in 
number, the optimal combination and sequencing of thera-
peutic modalities remains an area of intense investigation.
We hypothesized that real-world data describing the 
experience with HD IL-2 in the contemporary era of check-
point inhibitors and targeted therapies would better define 
the relevance of HD IL-2 in the context of these new thera-
pies. In an effort to study the real-world use of HD IL-2, 
an observational database, termed PROCLAIMSM (PRO-
LEUKIN® Observational Study to Evaluate the Treatment 
21 Present Address: Nektar Therapeutics, San Francisco, CA, 
USA
22 Cancer Research Foundation, Chappaqua, NY, USA
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Patterns and Clinical Response in Malignancy) was created 
in 2011 [27]. PROCLAIM is the largest patient registry in 
the world collecting data on IL-2 treatment outcomes, pro-
spectively from about 40 enrolled sites. The PROCLAIM 
registry is designed to generate new hypotheses from retro-
spective and prospective cohort analyses. Herein, we report 
survival and outcomes data from the retrospective cohort 
analysis, from the 16 sites that provided retrospective data, 




Within the PROCLAIM registry (ClinicalTrials.gov iden-
tifier: NCT01415167) [27], established in 2011, retro-
spective data from de-identified patient cases have been 
abstracted from existing charts of patients treated with HD 
IL-2 between January 2005 to February 2012. Sixteen sites 
participated in the retrospective database. Patients were at 
least 18 years of age, had a diagnosis of mM or mRCC, and 
had received at least 1 dose of HD IL-2. Sites were encour-
aged to enroll consecutive eligible patients. In the current 
report, data from 362 patients, including 170 mM and 192 
mRCC, were analyzed with the data extraction date of July 
27, 2015. Available baseline data from enrolled patients 
included demographics (sex, age, and race) and clinical dis-
ease characteristics [Eastern Cooperative Oncology Group 
performance status (ECOG PS), disease stage, primary 
site of metastasis, BRAF mutation status in mM patients if 
tested, and prior treatment]. Patient eligibility at each site 
was confirmed by a study coordinator, and an electronic 
data capture system was used to record the data. The reg-
istry was approved by the Institutional Review Board at all 
participating sites. All data were subject to quality control 
procedures. Among retrospectively collected cohort, no 
consent was obtained, and only survival data were collected 
in follow-up. Additionally, due to the retrospective nature 
of data collection and exemption from consent, no informa-
tion regarding subsequent IL-2 or other therapy post-IL-2 
was collected.
Treatment and assessments
Physicians managed and treated patients per each institu-
tion’s standard of care and their own clinical judgment. 
HD IL-2 (Proleukin®) was administered as an intravenous 
bolus every 8 h at a dose of 600,000 IU/kg or 720,000 IU/
kg as tolerated, with up to 14 consecutive doses over 5 days 
(1 cycle of therapy). Patients received a second cycle of 
HD IL-2 after approximately a 9-day rest period, per the 
discretion of the investigator. Two cycles of HD IL-2 treat-
ment constituted 1 standard course of HD IL-2 therapy. 
Additional courses were administered per the discretion 
of the treating physician. The duration of HD IL-2 drug 
administration was assessed from the time from the start 
of the first dose of HD IL-2 to the end of the last dose 
of HD IL-2 including rest periods. Response to HD IL-2 
was determined by the investigator using either World 
Health Organization (WHO) criteria or Response Evalua-
tion Criteria in Solid Tumors (RECIST), depending on the 
procedures utilized by the individual physician and site. 
Response was documented after each HD IL-2 treatment 
course (2 cycles) and approximately every 6 months upon 
conclusion of therapy
Statistical analyses
All statistical analyses were performed using SAS soft-
ware version 9.4. Patient characteristics, tumor response, 
and survival status were determined using data that were 
extracted on July 27, 2015. Frequency counts and measures 
of central tendency were performed to provide descrip-
tive statistics. One-year, 2-year, and 3-year survival prob-
abilities were obtained using the Kaplan–Meier product 
limit method and corresponding confidence interval (CI) 
were obtained using Greenwood’s formula. Kaplan–Meier 
curves with 95 % CIs were used to estimate mOS, with the 
log-rank test to determine significance (P < .05). OS was 
calculated from the date of first dose of HD IL-2 to date 
of death or date of most recent follow-up. Patients were 
followed until date of death or until last day of follow-up. 
Survival estimates for mRCC patients were also analyzed 
based on stratification into risk groups according to the 
International mRCC Database Consortium model (Heng 
criteria) [28]. The parameters included: ECOG PS ≥ 2, less 
than 1 year from initial diagnosis to treatment, hemoglobin 
concentration < lower limit of normal (LLN), calcium 
concentration > upper limit of normal (ULN), neutrophil 
count > ULN, and platelet > ULN. Patients were grouped 
into favorable (0 factors), intermediate (1–2 factors), and 




Demographic and disease characteristics for both mM 
and mRCC patients are listed in Table 1. There were 91 % 
(n = 154) mM and 94 % (n = 89) mRCC patients that 
reported stage IV disease; note that 97 patients did not 
have tumor stage data available and were not used in this 
1536 Cancer Immunol Immunother (2016) 65:1533–1544
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Table 1  Patient demographics and disease characteristics
mM mRCC Total
n = 170 % n = 192 % n = 362 %
Gender
Male 70 41 144 75 214 59
Female 100 59 48 25 148 41
Age
<65 149 88 168 88 317 88
≥65 21 12 24 13 45 12
Median 54 NA 56 NA 55 NA
Range 20–79 NA 19–74 NA 19–79 NA
Race
White 165 97 181 94 346 96
Black 4 2 2 1 6 2
Other 1 1 7 4 8 2
Decline 0 0 2 1 2 1
ECOG PSa
0 124 73 156 82 280 78
1 44 26 34 18 78 22
2 2 1 1 1 3 1
Missinga 0 0 1 1 1 0
Stageb
IIIc 8 5 NA NA 8 3
III/III NOS 0 0 2 2 2 1
IIIb/IVa 6 4 4 4 10 4
IV/IVNOS 36 21 89 94 125 47
M1a 11 6 NA NA 11 4
M1b 28 16 NA NA 28 11
M1c 79 46 NA NA 79 30
Other, specify 2 1 NA NA 2 1
Missingb 0 0 97 NA 97 37
mM mRCC Total
Had mutation testing
No 112 66 NA NA 112 31
Yesc 58 34 NA NA 58 16
BRAF+
Noc 17 30 NA NA 17 30
Not testedc 1 2 NA NA 1 2
Yesc 40 70 NA NA 40 70
Site of metastasis
Skin, lungs, LNs only 48 28 73 38 121 33
Other including skin, lungs, LNs 119 70 79 41 198 55
Not reported 3 2 40 21 43 12
Prior therapyd
Surgery 118 69 183 95 301 83
Radiation 49 29 15 8 64 18
Chemotherapy 32 19 5 3 37 10
Other immunotherapy 58 34 5 3 63 17
Targeted therapy 3 2 25 13 28 8
Blinded RCT 3 2 3 2 6 2
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calculation. Most patients had an ECOG PS of 0 (n = 124, 
73 % mM; n = 156, 82 % mRCC). Among the mM patients, 
only 57 (34 %) had BRAF mutation testing data available, 
and in this group, 40 tested positive for the BRAFV600E 
mutation. There were 58 (34 %) mM patients who had prior 
immunotherapy and 3 (2 %) who had prior targeted therapy. 
The database collected actual prior therapy, but did not 
specify whether prior immunotherapy was in the adjuvant 
setting. Among the mRCC patients, 183 (95 %) had a prior 
nephrectomy and 25 (13 %) had received prior targeted ther-
apy. Thus, in this treatment time frame (2005–2012), HD 
IL-2 was often the initial treatment for eligible advanced 
mRCC and mM patients registered in PROCLAIM.
IL‑2 administration
The duration of HD IL-2 drug exposure was assessed 
from the start of the first dose of HD IL-2 to the end of 
the last dose of HD IL-2 including the rest period. For 
censored patients (patients still alive), the median dura-
tion of HD IL-2 drug exposure including the rest period 
was 2.4 months (range 0.56–14.37) and 0.66 months (range 
0.06–12.99) for mM (n = 43) and mRCC (n = 89), respec-
tively. Melanoma patients more frequently received addi-
tional courses (Supplementary Table 1). For all patients 
with mM (n = 170), the median duration of HD IL-2 drug 
exposure was 0.84 months (range 0.10–14.37), and for all 
patients with mRCC (n = 192), the median duration was 
0.62 months (range 0.03–12.99). The number of doses of 
IL-2 per cycle for mM and mRCC are described in Supple-
mentary Table 1 and were no different from current prac-
tice or recent clinical trials and clinical reports [5, 7].
Tumor response
Response data were available for 158 patients (93 %) with 
mM: Eight patients (5 %) achieved CR, 16 (10 %) had PR, 
and 34 (22 %) had SD, while 100 (63 %) had progressive 
a ECOG PS based on patients with available data
b Sites were not required to enter in tumor stage for mRCC patients. Calculations were from patients with available data (95). Ninety-seven 
patients did not have tumor stage data
c BRAF mutation percentage was calculated from patients who had mutation testing
d Patients may have had multiple prior therapies. Percentages were calculated based on number of patients
NA not available, ECOG PS Eastern Cooperative Oncology Group performance status, NOS not otherwise specified, LNs lymph nodes, RCT 
research clinical trial
Table 1  continued
mM mRCC Total
Other 3 2 1 1 4 1
Untreated 34 20 5 3 39 11
Table 2  Summary and time to 
tumor response
a Responses are from patients identified after each course of HD IL-2 therapy with a final response
Final response % Course 1 Course 2 Course 3 Course 4 Course 5
mM n = (158)a
 CR 8 5 2 3 3 0 0
 PR 16 10 8 4 4 0 0
 SD 34 22 10 13 7 3 1
 PD 100 63 82 12 6 0 0
 CR + PR 24 15 10 7 7 0 0
 CR + PR + SD 58 37 20 20 14 3 1
mRCC (n = 185)a
 CR 12 6 6 6 0 0 0
 PR 17 9 3 11 2 0 1
 SD 41 22 23 10 4 4 0
 PD 115 62 103 8 4 0 0
 CR + PR 29 15 9 17 2 0 1
 CR + PR + SD 70 37 32 27 6 4 1
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disease (PD) (Table 2). The objective response rate (ORR), 
defined as CR + PR, was 15 %, and the clinical benefit rate 
(CBR), defined as CR + PR + SD, was 37 %. For patients 
with mRCC, data were available for 185 (96 %) patients. 
There were 12 (6 %) patients with CR, 17 (9 %) with PR, 
41 (22 %) with SD, and 115 (62 %) with PD (Table 2). 
The ORR in patients with mRCC was 15 %, and clinical 
benefit was observed in 70 (37 %) patients. CR, PR, or SD 
were frequently determined after course 2 of HD IL-2 treat-
ment (≥62 % in mM and >80 % in mRCC), while 82 % of 
mM and 90 % of mRCC patients with PD were identified 
after course 1 of treatment (Table 2). Therefore, the effi-
cacy of IL-2 can be determined in a relatively short period. 
Response rates were also analyzed based on prior treat-
ment. Therapies prior to IL-2 are listed in Supplementary 
Table 2. Seventy-seven melanoma patients and 30 RCC 
patients received prior therapy, and this could have been in 
the adjuvant setting. No further details have been recorded. 
Some clearly received prior treatment for advanced disease. 
The majority of these patients received 1 or 2 prior thera-
pies (Supplementary Tables 3, 4). In this database, there 
were no responses to IL-2 in patients who had 3 or more 
prior therapies.
Survival data
Survival estimates were calculated from the first dose of 
HD IL-2. For mM patients, the mOS was 19.6 months 
[95 % confidence interval (CI): 14.04, 24.10] with a median 
follow-up of 43.1 months (95 % CI 37.61, 46.13) (Fig. 1a). 
The mOS was not yet reached for those who experienced 
CR (n = 8) and PR (n = 16) (Fig. 1b). A statistically sig-
nificant difference in mOS was observed between the 
patients who experienced SD and those who had PD (33.4 
vs. 13.2 months; P < .0001) (Fig. 1b). There was no sta-
tistically significant difference in mOS between patients 
who experienced SD and PR. The 1-, 2-, and 3-year sur-
vival rates for patients with CR/PR were 91, 78, and 68 %, 
respectively. The 1-, 2-, and 3-year survival rates for 
patients with SD were 82, 73, and 47 %, respectively. An 
analysis of survival in patients who were systemic therapy-
naïve versus those with prior systemic therapy was per-
formed in the mM cohort. Prior systemic therapy included 
chemotherapy, targeted therapy, and/or immunotherapy. 
The mOS for patients without prior systemic therapy was 
20.0 months (n = 93) compared to 18.7 months (n = 77) 
for those with prior systemic therapy (P = .76, Supplemen-
tary Figure 1a).
The mOS for patients with mRCC was 41 months (95 % 
CI 32.6, 57.5) with a median follow-up of 46.6 months 
(95 % CI 41.8, 49.6) (Fig. 1c). Patients with CR (n = 12) 
and PR (n = 17) had not reached a median overall survival, 
while patients with SD (n = 41) had a mOS of 49.6 months 
(Fig. 1d). There was no statistically significant differ-
ence in mOS between patients who experienced SD and 
PR. Patients with PD (n = 115) experienced a mOS of 
32.6 months (Fig. 1d). There was a significant difference in 
mOS between the patients who experienced SD and those 
who had PD (49.6 vs. 32.6 months; P = .01 (Fig. 1d). The 
1-, 2-, and 3-year survival rates for patients with CR/PR 
were 94, 84, and 77 %, respectively. The 1-, 2-, and 3-year 
survival rates for patients with SD were 93, 72, and 63 %, 
respectively. An analysis of survival in patients who were 
systemic therapy-naïve versus those with prior systemic 
therapy was performed in the mRCC cohort. The mOS for 
patients without prior systemic therapy was 48.9 months 
(n = 162) compared to 16.4 months (n = 30) for those with 
prior systemic therapy (P = .03, Supplementary Fig. 1b).
There were no reported investigator assessed treatment-
related deaths for patients with mM or mRCC (N = 362).
BRAF mutation status for mM patients
BRAF mutation testing was performed in only 57 of the 
total 170 melanoma patients. The mOS was 25.2 months 
for patients with BRAFV600E mutation (n = 40) and was 
11.6 months for BRAF wild-type patients (n = 17) (data 
not shown). Of the patients with data available for response 
to IL-2, among those with BRAF mutation there were no 
CRs, 2 PR, 11 SD, and 25 PD, (data not shown). Among 
the BRAF wild-type patients, there were 3 CR, 2 PR, 1 
SD, and 9 PD. However, because the proportion of patients 
tested is a small subset, this data are provided for complete-
ness only.
Survival by risk factors for mRCC
To determine OS based on externally validated prognos-
tic risk factors for mRCC, patients were stratified into risk 
groups using the international mRCC Database Consortium 
model, also known as the Heng Criteria [28]. One hundred 
and forty-nine patients (78 %) had complete data for all 
six parameters and were included in this analysis. Thirty-
seven patients (25 %) were in the favorable-risk group, 95 
patients (64 %) were in the intermediate-risk group, and 
17 patients (11 %) were in the poor-risk group. The mOS 
for patients in the favorable-risk group was 63.7 months, 
while for patients in the intermediate- and poor-risk groups, 
the mOS was 34.3 and 18.4 months, respectively (Table 3, 
P = .054 favorable vs. intermediate, P = .001 favora-
ble vs. poor, P = 1.0 intermediate vs. poor). An analysis 
of response to HD IL-2 for the three risk groups was also 
performed (Table 3). For patients in the favorable group, 
there were 2 CR, 1 PR, 9 SD, and 25 PD. In the interme-
diate group, there were 9 CR, 4 PR, 17 SD and 60 PD. In 
the poor-risk group, there were 0 CR, 3 PR, 5 SD and 7 
1539Cancer Immunol Immunother (2016) 65:1533–1544 
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PD. Additionally, survival by risk category is presented in 
Table 3, with data from the Heng report [28] (targeted ther-
apy) and the first Motzer report [29] (interferon therapy) 
provided for reference.
Survival by time of HD IL‑2 treatment
Although no data are available on post-IL-2 treatments, we 
have post hoc evaluated survival among cohorts of patients 
(a) (c) mRCCmM
Median OS=19.6 months
95% CI (14.04, 24.10)
Median F/U=43.1 months




95% CI (32.6, 57.5)
Median F/U=46.6 months








P<.0001 SD vs. PD





P=.01 SD vs. PD
P>.05 SD vs. PR
Fig. 1  Overall survival in patients treated with HD IL-2 a Median OS (mM). b Median OS by response (mM). c Median OS (mRCC). d Median 
OS by response (mRCC). Vertical bars represent censored subjects. NR, not reached; F/U, follow-up
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treated with HD IL-2 in the early years of the retrospec-
tive registry (2005–2009) and the later years (2010–2012), 
when more subsequent therapies were available. As can be 
seen in Fig. 2a, b, for mM and in Fig. 2c, d for mRCC, the 
survival is very similar.
Discussion
The PROCLAIM observational database informs upon the 
real-world use and outcome of HD IL-2 for mM and mRCC 
patients in the era of TT and checkpoint immunotherapy. 
This retrospective analysis of contemporary patients with 
mM and mRCC receiving HD IL-2 revealed improved 
median overall survival compared to the historical experi-
ence. Single institution reports of IL-2 treated patients also 
show improvement in OS compared to historical experi-
ence [5, 30] as has a prospective multi-institutional study 
in mRCC (SELECT) [7]. Therefore, the PROCLAIM 
observational database demonstrates consistency with these 
reports [31, 32].
In this report, data were included from patients treated 
between 2005 and 2012, and even so, many of these 
patients received HD IL-2 as their initial treatment for 
advanced disease (mM no prior systemic treatment, 
N = 93; prior systemic treatment, N = 77; mRCC no prior 
systemic treatment, N = 162, prior systemic treatment, 
N = 30). However, they were treated during a transition 
period in which new agents were in development in clini-
cal trials in both mRCC and mM, and eventually commer-
cially, providing options for follow-on treatment. The clini-
cal trials available to these patients in that era were either 
for patients who had progressed on prior treatment, or for 
newly diagnosed patients. Eventually, commercial drugs 
were available for patients with mRCC (2006) and for mM 
(2011).
As has been noted in clinical trials of the newer targeted 
therapies and more recently checkpoint inhibitors, sur-
vival of patients with advanced disease has improved, and 
patients are able to receive multiple sequential treatments 
with different mechanisms of action. Importantly, 43 % 
of HD IL-2-treated patients in this retrospective cohort 
achieved SD as best response. We have evaluated the out-
come of treatment with HD IL-2 by best response and have 
observed prolonged OS in patients with SD, compared to 
patients with PD (Fig. 1b, d). We are exploring the poten-
tial impact of SD on OS as a consequence of HD IL-2 ther-
apy in our prospective cohort versus simply the effect of 
follow-on therapy.
Because the data presented here reflect a retrospec-
tively collected database, we do not have specific data on 
the treatment(s) patients received post-IL-2 progression. 
However, we have evaluated OS in the group treated with 
HD IL-2 between 2005 and 2009 versus between 2010 and 
2012, possibly indicating that more subsequent therapy was 
available in the later time frame, but without information 
regarding the subsequent treatment of the patients in this 
retrospective cohort. As can be seen from Fig. 2a, b for 
melanoma and Fig. 2c, d for renal cell cancer, there is no 
significant difference in OS between the two time periods. 
This is surprising given the expected increased access to 
subsequent therapy in the later years. However, this infor-
mation is derived from a retrospective database and could 
reflect selection bias of patients entered, small numbers in 
Table 3  Survival and response of mRCC to IL-2 (PROCLAIM) by Heng criteria
Responses were based on patients with available data
a PROCLAIM median follow-up was 46.6 months
b Heng DY et al., JCO 2009, 27(34): 5794–9. Median follow-up was 24.5 months
c Motzer RJ et al., JCO 1999, 17(8): 2530–40. Median follow-up was 33 months
Favorable (median survival, months) Intermediate (median survival, months) Poor (median survival, months)
PROCLAIMa 63.7 (n = 37) 34.3 (n = 95) 18.4 (n = 17)
Hengb Not reached 27 8.8
Motzerc 20 10 4
PROCLAIM response by Heng model Favorable Intermediate Poor
N % N % N %
CR 2 5.4 9 9.5 0 0
PR 1 2.7 4 4.2 3 17.7
SD 9 24.3 17 17.9 5 29.4
PD 25 67.6 60 63.2 7 41.2
Missing 0 0 5 5.3 2 11.8
Total 37 100 95 100 17 100
1541Cancer Immunol Immunother (2016) 65:1533–1544 
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the earlier group, or possibly an effect of HD IL-2 on both 
groups. This will need to be the subject of future investiga-
tions, and no conclusions can be drawn from this dataset.
This retrospective cohort analysis provides a means of 
generating hypotheses to test in prospectively collected 
patient treatment records, which is ongoing. A major focus 
of the prospective PROCLAIM database is to evaluate the 
safety and efficacy of sequential treatments for mRCC and 
mM, and data on all treatment modalities are being col-
lected, both prior and follow-on treatment. We will con-
tinue to evaluate the impact of SD on long-term outcome, 
as well as the potential for synergy among immunotherapy 
treatments. We will also evaluate the safety and efficacy of 
administration of HD IL-2 subsequent to the newer targeted 
and immunotherapy approaches.
Additional analyses of this retrospective cohort include 
an evaluation of the effect of prior therapy on outcome from 
IL-2. As noted in Supplementary Figure 1, there was a sig-
nificant effect among patients with mRCC, but not significant 
among patients with mM. In part, this may be because much 
of the prior systemic treatment for mM was interferon and it 
was likely (not documented in the database) given as adjuvant 
therapy. However, this could also reflect a negative impact of 




Fig. 2  In order to determine the effect of targeted therapies on sur-
vival, patients were grouped into 2 cohorts based on years prior to 
or post targeted therapy approval (1 cohort from 2005–2009 and 1 
cohort from 2010–2012). a Median OS for mM patients from date of 
first dose of IL-2 with a 2 year cutoff. b Median OS in mM patients 
from first dose of IL-2 to the last follow-up. c Median OS for mRCC 
patients from date of first dose of IL-2 with a 2 year cutoff. d Median 
OS in mRCC patients from first dose of IL-2 to the last follow-up
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prior targeted therapy) on outcome for patients with mRCC. 
Both of these hypotheses provide additional questions to pose 
from the PROCLAIM prospective cohort, and these analyses 
will be available with more detail from that cohort.
Although data on B-RAF mutation status were collected, 
it was not available for two-thirds of the subjects. There-
fore, analysis of IL-2 outcome based on mutational status 
is only exploratory and will require prospective collection 
of this information. To date, there has been no evidence that 
B-RAF mutation status impacts the clinical response to HD 
IL-2 treatment.
Among the mRCC patients, prognostic subgroup infor-
mation was evaluated, and in Table 3 we provide the 
response data to HD IL-2 by subgroup. Surprisingly, all 
subgroups have evidence of major response. Additionally, 
in Table 3, we have delineated the overall survival among 
the patients in this retrospective cohort by prognostic group 
alongside the results from the original reports by Heng 
et al. [28] of the factors among targeted therapy-treated 
patients and the original Motzer et al. [29] report in patients 
treated with interferon. It is gratifying to see that there is 
continued survival improvement over time with each suc-
cessive report.
In summary, we report an analysis of a retrospectively 
accrued cohort from the PROCLAIM observational data-
base of real-world patients treated in the modern era of HD 
IL-2 (2005–2012). We have demonstrated that these patients 
received similar dosing of HD IL-2 compared to clinical 
trials and that patient demographics reflect prior reports of 
these populations. Prior therapy may have an impact on out-
come of mRCC patients subsequently treated with HD IL-2, 
compared with melanoma patients. Alternatively much of the 
prior therapy for the melanoma patients may have been in 
the adjuvant setting, such that prior treatment did not impact 
on effect of HD IL-2. Finally, patients achieving SD after 
IL-2 had improved OS compared to PD patients, as was also 
noted in the prospective IL-2 SELECT RCC trial [7]. We are 
evaluating the outcome of SD patients prospectively, and we 
are investigating the impact of sequential therapy and when 
these are given in the course of the disease (at SD or PD) 
among all IL-2 treated patients in the prospective cohort of 
the PROCLAIM observational database.
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